We speak with Lauren Taus who is the Founder of INBodied Life, who's focus is on integrating modern science and ancient wisdom to support transformation.
Similar Posts
The Top 10 Psychedelics Stocks’ Financials COMPARED ( Atai, CMPS, MNMD, NUMI, RVV, DMT, TRIP+)
What’s up psychedelic investors! In this episode, we’ll be comparing the top 10 psychedelic stocks’ financials.
Will look at the 4 most important financial stats for each of the top 10 companies in the Psychedelic Medicines field, selected by market cap.
First, we will look at the market cap, because that tells us how valuable the market judges the company to be, and it tells us how easily a company can raise capital.
Next, we will look at cash on hand.
Third, we will look at how much a company is spending.
Finally, we will look at revenue where applicable
All figures are in American dollars.
So which stocks we’ll be comparing, you may ask? We’ll look at:
– Atai Life Sciences ( NASDAQ: ATAI)
– Compass Pathways (NASDAQ: CMPS)
-MindMed (NASDAQ: MNMD), ( NEO: MMED)
– Cybin Inc (NYSE: CYBN)
– Numinus Wellneass (TSX: NUMI) (OTC: LKYSF)
– Revive Therapeutics (CN: RVV) (OTC: RVVTF)
– Small Pharma ( TSX: DMT)
-Mydecine (OTC: MYCOF) (NEO: MYCO)
– Red Light Holland ( CSE: TRIP) (OTC: TRUFF)
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #ATAISTOCK #PsychedelicStocks
What are the Benefits of MICRODOSING Psilocybin? | Interview with a Microdosing Expert
What are the benefits of Microdosing psilocybin? | Interview with a Microdosing Expert
In today’s episode, we sit down with microdosing expert Sena Maria of The Medicine of Being Human and MicrodosingForResilience.com.
In this interview, we learn about Sena’s microdosing business, which helps people begin microdosing psilocybin (note she does not provide any illegal substances, only coaches people on how to microdose) and the benefits that microdosing can bring.
For example, Sena gives us a fantastic Top 5 Benefits of Microdosing at some point in our chat.
Some of the questions that we covered were:
-What is microdosing and what are the benefits?
-How/ why did you start microdosing ?
-What is your microdosing regiment?
-What benefits have you personally seen from this?
-What do you wish people knew about psychedelics that they don’t currently?
-Can Microdosing magic mushrooms help with addiction?
-Can microdosing help treat depression or anxiety?
On top of discussing the how and why of microdosing psychedelics, Sena also discussed how these medicines have been known for generations in some aboriginal tribes, and how Western Medicine may still have a lot to learn.
Timestamps
00:00- Intro
1:32 – Sena Maria’s journey to microdosing: From Google to Psychedelics
4:15- Microdosing For Resilience
5:58- How to microdose psilocybin
8:20- Top 5 benefits of Microdosing
13:31- What is missed in the psychedelics conversation?
18:34- Sena’s Psychedelic Ceremony experiences
22:05 – How did you integrate what you learned in your psychedelic ceremony
#Microdosing #MicrodosingBenefits #Psychedelics
MAPS Phase 3 MDMA To Treat PTSD Trial Results: WOW [GREAT News For NUMI, MindMed, MYCO & Atai ]
MAPS Phase 3 MDMA To Treat PTSD Trial Results Released [ GREAT NEWS For NUMI, MindMed, MYCO & Atai ]
Breaking NEWS: 67% of participants in a recent MAPS sponsored Phase III clinical trial focused on MDMA- assisted therapy no longer qualified for a diagnosis of PTSD, compared with 32% in the placebo group. Also, 88% of participants receiving psychedelic therapy experiences a clinically significant reduction in symptoms of PTSD.
Also, there were 0 cases of serious adverse side effects in the MDMA group.
So which companies will be the largest benefactors of these results?
Numinus Wellness (NUMI / LKYSF ): working in conjunction with MAPS in Canada to conduct a compassionate access trial to those with PTSD. The trial is either already recruiting patients, or is set to do so imminently
2.MindMed ( MMED / MNMD / MMQ) is also working with MDMA, and has recently completely a study on personalized dosing of MDMA. MindMed also has a Phase I trial looking at the effects of combining LSD with MDMA.
3. Atai life sciences is in the preclinical stages of using an MDMA derivative to treat PTSD, through their subsidiary EmpathBio.
4. Mydecine has a compound called MYCO-002, which is similar to MDMA, which they hope to start using in clinical trials soon.
5. Awakn Life Sciences, a private company, also will have a Phase II study looking at treating alcohol use disorder with MDMA.
Link to the article in question: https://www.nytimes.com/2021/05/03/health/mdma-approval.html?fbclid=IwAR3xMWgnKryfZnzWqB7mJ9GrkVuoQE79yC-kVEXJzOyF4n7JEcHOuobw7jQ#click=https://t.co/GVhm9i2wm3
Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/
Link to MYDECINE ( MYCO / MYCOF ): https://www.mydecine.com/
Link to Numinus (NUMI): https://numinus.ca/
Link to Atai Life Sceinces : https://www.atai.life/
Link to Awakn Life sciences: https://www.newsfilecorp.com/company/7226/Awakn-Life-Sciences-Inc.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Clinical trials :
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #NUMIStock
Health Canada’s Dealer’s Licence & Section 56 Explained with Benjamin Lightburn
Benjamin Lightburn of Filament Health discusses the ins and outs of being a licensed dealer of naturally derived psilocybin in Canada and internationally.
Riley Cote – From NHL Enforcer to Psychedelic Therapy Advocate
On this episode of the Psychedelic Spotlight Podcast, our host David Flores catches up with former Philadelphia Flyer and NHL enforcer, Riley Cote who in recent years has become one of the most prominent and outspoken advocates for psychedelics and psychedelic-assisted therapy through his work with the Wake Network and RileyCote.com.
Using Mycelium for a Sustainable Future feat. Kimberly Carlson
Join David in this engaging episode as he converses with Kimberly Carlson, CEO & CFO of Mushrooms Inc., a pioneering company at the forefront of driving sustainable practices through innovative mycelium applications.